Privia Health Group, Inc. (PRVA)
NASDAQ: PRVA · Real-Time Price · USD
22.42
-0.17 (-0.75%)
Mar 31, 2025, 9:55 AM EDT - Market open
Privia Health Group Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Privia Health Group stock have an average target of 26.56, with a low estimate of 20 and a high estimate of 40. The average target predicts an increase of 18.47% from the current stock price of 22.42.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Privia Health Group stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 6 | 6 | 6 |
| Buy | 7 | 7 | 7 | 8 | 10 | 9 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 16 | 17 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +33.81% | Mar 21, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $26 → $29 | Buy | Maintains | $26 → $29 | +29.35% | Feb 28, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $29 → $30 | Strong Buy | Maintains | $29 → $30 | +33.81% | Feb 28, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $25 → $40 | Buy | Maintains | $25 → $40 | +78.41% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Maintains $25 → $30 | Strong Buy | Maintains | $25 → $30 | +33.81% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
3.28B
from 1.74B
Increased by 88.90%
Revenue Next Year
3.64B
from 3.28B
Increased by 10.98%
EPS This Year
0.25
from 0.11
Increased by 129.17%
EPS Next Year
0.38
from 0.25
Increased by 50.29%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.4B | 3.9B | 4.5B | ||
| Avg | 3.3B | 3.6B | 4.0B | ||
| Low | 3.1B | 3.4B | 3.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 96.2% | 17.8% | 23.4% | ||
| Avg | 88.9% | 11.0% | 11.2% | ||
| Low | 79.7% | 4.1% | 1.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.39 | 0.84 | 0.64 |
| Avg | 0.25 | 0.38 | 0.47 |
| Low | 0.18 | 0.27 | 0.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 253.2% | 233.2% | 69.1% |
| Avg | 129.2% | 50.3% | 23.4% |
| Low | 60.4% | 8.9% | 3.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.